Search Results - "Eechoute, K."

Polymorphisms in Endothelial Nitric Oxide Synthase (eNOS) and Vascular Endothelial Growth Factor (VEGF) Predict Sunitinib-Induced Hypertension by Eechoute, K, van der Veldt, A A M, Oosting, S, Kappers, M H W, Wessels, J A M, Gelderblom, H, Guchelaar, H-J, Reyners, A K L, van Herpen, C M L, Haanen, J B, Mathijssen, R H J, Boven, E

“…Hypertension is an important side effect of sunitinib treatment. In a retrospective study in 255 patients, single‐nucleotide polymorphisms (SNPs) in vascular…”
Get full text

Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2 by Eechoute, K, Franke, RM, Loos, WJ, Scherkenbach, LA, Boere, I, Verweij, J, Gurney, H, Kim, RB, Tirona, RG, Mathijssen, RHJ, Sparreboom, A

“…The bioavailability of orally administered imatinib is >90%, although the drug is monocationic under the acidic conditions in the duodenum. In vitro, we found…”
Get full text

Myelosuppression by sunitinib is flt-3 genotype dependent by van Erp, N P, Mathijssen, R H J, van der Veldt, A A, Haanen, J B, Reyners, A K L, Eechoute, K, Boven, E, Wessels, J A M, Guchelaar, H-J, Gelderblom, H

Get full text

Correlation between imatinib trough levels and clinical benefit in gastrointestinal stromal tumors (GIST): Results of a prospective population pharmacokinetic study by Eechoute, K., Fransson, M. N., De Giorgi, U., Reyners, A. K. L., de Jong, F. A., Friberg, L. E., Van Der Graaf, W. T., Sparreboom, A., Verweij, J., Loos, W. J., Mathijssen, R.

“…Abstract only…”
Get full text

382 Influence of rosuvastatin on the pharmacokinetics of imatinib: a cross-over study by Eechoute, K, Franke, R.M, Loos, W.J, de Bruijn, P, Verweij, J, Sparreboom, A, Mathijssen, R.H.J

Get full text

A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients by EECHOUTE, Karel, FRANSSON, Martin N, LOOS, Walter J, MATHIJSSEN, Ron H. J, DE GIORGI, Ugo, REYNERS, An K, DE JONG, Floris A, SPARREBOOML, Alex, VAN DER GRAAF, Winette T. A, FRIBERG, Lena E, SCHIAVON, Gaia, WIEMER, Erik A. C, VERWEIJ, Jaap

“…Imatinib minimal (trough) plasma concentrations after one month of treatment have shown a significant association with clinical benefit in patients with…”
Get full text

Prospective analysis in GIST patients on the role of alpha-1 acid glycoprotein (AGP) in imatinib exposure by Bins, S., Eechoute, K., Kloth, J.S.L., de Man, F.M., Oosten, A., de Bruijn, P., Sleijfer, S., Mathijssen, R.

Get full text

Predictive Value of Two Phenotyping Probes for the Pharmacokinetics of Sunitinib in Cancer Patients by Kloth, J.S.L., Klumpen, H.J., Samer, C.F., Eechoute, K., Lankheet, N.A.G., Kam, B.L., Wong, M., Schellens, J.H.M., Mathijssen, R.H.J., Gurney, H.

Get full text

1678P - Predictive Value of Two Phenotyping Probes for the Pharmacokinetics of Sunitinib in Cancer Patients by Kloth, J.S.L., Klumpen, H.J., Samer, C.F., Eechoute, K., Lankheet, N.A.G., Kam, B.L., Wong, M., Schellens, J.H.M., Mathijssen, R.H.J., Gurney, H.

“…Cancer patients treated with sunitinib show a wide inter-patient variability in drug exposure. This may at least partly explain the variation in toxicity and…”
Get full text

Tumor volumes measurement (3D) versus Response Evaluation Criteria in Solid Tumors (RECIST version 1.1, 1D) and Choi criteria (C) in assessing response of gastrointestinal stromal tumors (GIST) to imatinib (IM) by Schiavon, G., Ruggiero, A., Sleijfer, S., Eechoute, K., Krestin, G. P., Verweij, J., Mathijssen, R.

“…Abstract only…”
Get full text

Polymorphisms in Endothelial Nitric Oxide Synthase (eNOS) and Vascular Endothelial Growth Factor (VEGF) Predict Sunitinib-Induced Hypertension: INDIVIDUALIZATION by EECHOUTE, K, VAN DER VELDT, A. A. M, MATHIJSSEN, R. H. J, BOVEN, E, OOSTING, S, KAPPERS, M. H. W, WESSELS, J. A. M, GELDERBLOM, H, GUCHELAAR, H.-J, REYNERS, A. K. L, VAN HERPEN, C. M. L, HAANEN, J. B

Get full text

Single-nucleotide polymorphisms (SNPs) in the endothelial nitric oxide synthase (NOS3) and vascular endothelial growth factor (VEGF) and its relationship to sunitinib-induced hypertension by van der Veldt, A. A., Eechoute, K., Oosting, S., Kappers, M. H., Haanen, J. B. A. G., Reyners, A. K. L., Gelderblom, H., Guchelaar, H., Van Herpen, C., Boven, E., Mathijssen, R.

“…Abstract only…”
Get full text

Pharmacogenetic factors predicting the need for a higher dose of imatinib by Klumpen, H., Eechoute, K., Hertzberg, M. S., Schwarer, A. A., Goldstein, D., Hughes, T. P., Liddle, C., Mathijssen, R., Schellens, J. H., Gurney, H.

“…Abstract only…”
Get full text

Pharmacogenetic pathway analysis to identify factors for survival in metastatic renal cell cancer patients treated with sunitinib by Eechoute, K., van der Veldt, A. A., Gelderblom, H., Gietema, J. A., Guchelaar, H., Van Erp, N., Boven, E., Haanen, J. B., Mathijssen, R., Wessels, J. A.

“…Abstract only…”
Get full text

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity by van Erp, N., Mathijssen, R. H., van der Veldt, A. A., Haanen, J. B., Reyners, A. K., Eechoute, K., Boven, E., Wessels, J. A., Guchelaar, H., Gelderblom, H.

“…Abstract only 5006 Background: To identify genetic markers in the pharmacokinetic and pharmacodynamic pathways of sunitinib that predispose for development of…”
Get full text